Wells Fargo still thinks Monte Rosa Therapeutics is a good buy but cut its price target from $29 to $25.

Nov 7, 2026, 10:12 AM ETOpinionRead the original at moomoo.com

Neutral

Wells Fargo kept its Buy rating but lowered its target from $29 to $25. Because these are mixed analyst views, not a company update, they do not change Monte Rosa's outlook.

GLUE · Monte Rosa Therapeutics, Inc.

AI read · Neutral

The AI's read

The kept rating shows the analyst still expresses confidence in Monte Rosa. The lower target points to a weaker view of what the shares are worth. The story reports no company change, so these mixed signals do not change the business outlook.

Get alerts for GLUE

Follow Monte Rosa Therapeutics, Inc. (GLUE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GLUE

Free on the App Store and Google Play, or on the web.